Screen Shot 2019-06-20 at 2.30.50 PM.png
Fund.png
RobSarrazin.jpg

Mr. Sarrazin is Chief Investment Officer and Managing Partner of the Autism Impact Fund where he
oversees the firm and leads AIF’s Life Sciences practice. Rob’s career as a longtime healthcare investor,
private equity partner and corporate development executive includes decades of experience overseeing
a large portfolio of control investments, including corporate strategic transactions
and over 30+ middle market growth acquisitions under multiple private equity funds.


Most recently, Rob was the VP Global Head of External Innovation and Direct Investments for the
GlaxoSmithKline (“GSK”) Consumer Healthcare division, where he built a new strategically focused
corporate development capability. Rob managed a global team, reviewed over 7,000 medical
innovations and start-ups, and closed 30+ transactions with emphasis on digital devices, AI and
diagnostics, neuromodulation, microbiome, Rx to OTC Switch, bio-actives, and category line extensions.
Rob played a critical role in developing several strategic initiatives at GSK focused on transforming the
future of self-care, looking to give consumers and patients more control over their healthcare choices.

 

Prior to working at GSK, Rob was a Senior Partner at CSW, a private equity firm specializing in buyouts,
recapitalizations, and growth capital transactions in middle market companies. Before working at CSW,
Rob worked for 16 years for the private equity division of Charter Oak Partners, where he focused on
middle market control acquisitions across the healthcare, consumer products and industrials sectors.

 

Rob is a skilled life sciences investor and team builder with experience bringing together corporates,
startups, academics, and individual inventors. Rob is dedicated to leveraging his unique background,
combining senior operational roles and private equity partner experience, to catalyze change for the
autism community.

 

Rob has a bachelor’s degree in business administration from Richard Ivey Business School (Canada) and
an MBA from the Leonard N. Stern School of Business, New York, NY (Valedictorian).

  • LinkedIn
CRM-Headshot-7.20.20.jpg

Mr. Male is Co-Founder and Managing Partner of the Autism Impact Fund where he oversees the
firm and leads AIF’s Business Services practice.  Chris’ investment career includes a decade-plus of
leading venture and middle-market equity financing across business services, impact, legal cannabis
and real estate.
 
Prior to founding AIF, Chris was Managing Director of RBG Capital LLC, his family’s private
investment arm, where he was responsible for sourcing, structuring, negotiating transactions and
supporting portfolio management teams execute on value creation strategies.  Currently, he is a
board member of Quantum Power GmbH, On Point Market Research Group and ACME Glass and,
prior to the sale of each company, was on the boards of Dope Media LLC, Calyx Brands, and
Headset.
 
Chris also co-founded two successful investment vehicles in the legal cannabis space: (i) Anslinger
Capital, founded in 2014 and merged with Hypur Ventures in 2016, is fully deployed and returning
gains to investors and (ii) Revel Holdings, a curated investment vehicle for strategic family offices
and UHNW individuals to deploy capital in the space.  Prior to joining RBG, Chris was a Manager in
Hyatt Hotel’s Global Real Estate & Development Finance group.​

Chris’ youngest child, Duke, was diagnosed with Autism at three-years-old.  Chris is actively involved
with Quest Inc., a local nonprofit that “through quality and innovation build communities where
people with disabilities can achieve their goals” and he is committed to being a catalyst for
wholesale changes that improve the lives of people with autism and their families.

Chris holds an M.B.A. in Finance and Strategy from Case Western University’s Weatherhead School
of Management and a B.A. in History and Economics from Denison University.

He lives in Winter Park, Florida with his wife and three children.

  • LinkedIn

An innovative and patient-oriented scientist, Ashok Srinivasan has an extensive history of
scientific, clinical, and leadership achievement.

As the Translational Research Scientist for NSABP Foundation/NRG Pittsburgh, Ashok has
dedicated the past seven years to translating scientific advances to clinical trials, supporting new
technology and therapeutic advancements for breast and colorectal cancer. In this role, Ashok has
consulted as a molecular genetics / genomics expert in developing scientific rationales for 10+
clinical trials and educated clinical trialists on emerging trends and best practices in oncology
research. He has also been instrumental in generating scientific documentation for intellectual
property and patent application filings.


Ashok spearheaded the implementation and management of one of the first Next-Generation
Sequencing (NGS) facilities in Pittsburgh. As the NGS Facility Director at the University of
Pittsburgh and as a Translational Scientist at the NSABP, he guided a team of technicians and
postdoctoral fellows in the genomic analysis of genetic disease. His research focused on NGS
based analysis, genome and transcriptome sequencing, mutational analyses, the identification of
disease genes (zebrafish, mouse, human), ribosome profiling, and metagenomics. He was also
instrumental in viral threat research investigating viral recombination and virus evolution for
Project Prophecy.


Additionally, Ashok has served as a Staff Scientist at NHLBI/NIH and a Research Assistant Professor
at the University of Pittsburgh, Department of Biological Sciences.


Ashok earned a Ph.D. in Molecular Biology from the University of Pittsburgh and a Bachelor of
Science in Biology from the University of Madras. He was an Inlaks Scholar in Genetics at the
University of Cambridge, England. He has held postdoctoral research fellowships at Harvard
Medical School and the Cardiovascular Research Center at the Massachusetts General Hospital,
where he led a team that completed the zebrafish genetic map.

Ashok brings a valuable combination of knowledge and experience in model systems (viruses,
zebrafish, mouse) and human clinical trials. In addition to his wet-lab expertise in virology,
molecular biology, genetics, developmental biology, genomics, cardiovascular biology, and
oncology, he is also proficient in data science, statistics, and programming. His hands-on approach
to research combined with his leadership and training skills enable him to create, build, and
develop passionate and productive teams driving innovative applications of cutting-edge research.

Ashok has authored and co-authored more than 20 publications in basic and clinical research. His
primary motivation is overcoming barriers to effective precision medicine, the data-driven improvement
of therapeutic outcomes for patients, and translating insights from oncology to ASD. The heterogeneity
of ASD parallels that of cancer. However, in the absence of proven ASD biomarkers, molecular subtyping has not been achieved. The transformation of cancer multi-omics, immuno-oncology, and
metagenomics into technologies capable of manipulating the genome, proteome, immune system, and
microbiome for therapeutic ends has the potential to alter diagnosis and treatment strategies for many
diseases, including ASD, profoundly impacting human health.

  • LinkedIn
unnamed.png

Katie Mangialardi, Associate, invests on behalf of the firm’s Life Sciences and Life Span Services divisions, and has spent her career working at the intersection of healthcare and finance. Katie was previously an Associate at J.P.Morgan, where she worked across both Derivatives Sales and Acquisition  Leveraged Finance. At J.P.Morgan, Katie helped financial sponsors and corporate clients mitigate risk via derivatives execution and raise over $2 billion in the debt capital markets on the back of strategic transactions, M&A, restructuring, and refinancing activity.


Katie holds a B.S. in Biology of Global Health from Georgetown University, where she was a George F.
Baker Scholar. During her undergraduate career, she focused on engaging the private sector in global
health development through work with the United Nations and Gavi, the Vaccine Alliance. Katie also
worked as a researcher at Columbia University’s Program for Imaging and Cognitive Sciences, where she concentrated on conducting novel neuroeconomics research and was selected as a two-time presenter at Intel’s International Science and Engineering Fair.

  • LinkedIn
 
 
 
 
 
Screen Shot 2021-05-17 at 9.13.22 PM.png

Kelly Patterson, Head of Investor Relations & Fund Administration, is responsible for managing all relationship activity, in addition to fund administration, for AIF.  Prior to joining AIF, Kelly worked for 18+ years in the professional sports and entertainment space (National Hockey League, Major League Baseball, NJ Devils, Universal Music Group) managing key corporate and consumer products partners.  Kelly has inked lucrative endorsement deals and created bespoke marketing platforms for her clients; utilizing major events such as the World Series, Stanley Cup and various All Star Games. 

Kelly pioneered licensing and marketing programs, for athletes, teams and artists, creating explosive financial growth and resulting in expanded brand recognition for her clients.

 

Kelly holds a B.A. in fine arts from Colby College where she played ice hockey.  She currently lives in

Far Hills, NJ with her husband, newborn son and two dogs. 

  • LinkedIn